BETHESDA, Md., Nov. 1, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (Northwest Bio) today announced, as part of its program of public outreach and education, the availability online of an interview of Northwest Bio Chairman and CEO Linda Powers by CEO/CFO Publication.
The interview describes in layman's terms both the encouraging science behind DCVax® and the progress now being made in both the US and Europe towards being able to make this promising technology available to cancer patients.
By way of historical background, Ms. Powers observes that, "What attracted me to Northwest Biotherapeutics was that they have a platform technology that should be applicable to pretty much all cancers, and which is offering really a major improvement in survival times for patients, with no toxicity. The drugs that are out there today typically only add ten weeks of survival and they have a heck of a toxicity profile. Therefore, the combination of the effectiveness, the lack of toxicity, and the fact that it may be applicable to any cancer really was very exciting."In describing the technology, Ms. Powers noted, "The key to the Northwest technology was figuring out, number one, which type of immune cell is the master immune cell. In other words, who the General of the Army is, because if you are going to give the key signals, the marching orders, you have to give them to the right party who can implement them. Therefore, one key thing was figuring out that the dendritic cells are the master cells of the immune system. The immune system has so many players." The full interview is available on the Company's website, www.nwbio.com as well as on http://ceocfointerviews.com, CEO/CFO Publication's website. About Northwest Biotherapeutics Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products in both the US and Europe to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax® for metastatic ovarian cancer. For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com. Also follow us on Twitter @NorthwestBio. Disclaimer Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws. SOURCE Northwest Biotherapeutics
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.